Raised Lp(a) Slashed in CV Patients on Novel Antisense Agent

Treatment with a proprietary antisense agent was associated with significant reductions in levels of lipoprotein(a) in a phase 2 study of patients with established coronary or peripheral vascular disease and elevated Lp(a).

External link

 

 

Related stories